// App-Quantinova.ai

1492 : Therapeutic Utility of PI3K? Inhibition in Leukemogenesis and Tumor Cell Survival

Researchers

Presenter

  • Dosh Whye

Principal Investigators

  • Evgeni Efimenko

  • Adolfo A. Ferrando

  • Brian J. Lannutti

  • Prem Subramaniam

  • Jianchung Chen

  • Valeria Tosello

  • Kim de Keersmaecker

  • Adam Kashishian

  • Mary Ann Thompson

  • Mireia Castillo

  • Carlos Cordon-Cardo

  • Utpal P. Dave

Medical Centers

  • Neonatology and Perinatology, Columbia University Medical Center, New York, NY

  • Division of Pathology, Mount Sinai School of Medicine, New York, NY

Locations

  • United States

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Hematological malignancies

  • Solid malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Idelalisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved